Page 7 of 96 FirstFirst 123456789101112131415161757 ... LastLast
Results 61 to 70 of 960

Thread: Spinal Cord Injury Articles Posted by Manouli

  1. #61
    Senior Member lunasicc42's Avatar
    Join Date
    Oct 2004
    Lutz, Fl USA*********C456
    well, I must say I like it because the thread "stemcell articles " has posts that are relative to stemcells for anything. Sorry but it rarely concerned me much. This thread is more specific all about spinal cord injury information.
    "That's not smog! It's SMUG!! " - randy marsh, southpark

    "what???? , you don't 'all' wear a poop sac?.... DAMNIT BONNIE, YOU LIED TO ME ABOUT THE POOP SAC!!!! "

    2010 SCINet Clinical Trial Support Squad Member
    Please join me and donate a dollar a day at and copy and paste this message to the bottom of your signature

  2. #62
    July 25, 2011 11:59 AM Eastern Daylight Time
    MossRehab First in the U.S. to Offer Therapeutic Use of ReWalk™ Device

    PHILADELPHIA--(BUSINESS WIRE)--In a groundbreaking move, MossRehab, one of the nation’s leading rehabilitation centers, will be the first facility in the country to offer ReWalk ™ – I, an institutional version of ReWalk™, the only motorized exoskeleton that is approved by the FDA to be used in a rehabilitation setting under the supervision of healthcare professionals. Patients with paralysis below the waist resulting from a spinal cord injury will be able to participate in gait training using ReWalk. The therapeutic use of ReWalk, also called ReWalking, involves physical therapists training patients to use the device to stand, sit, walk, and in some cases climb and descend stairs.

    This next stage in ReWalk’s evolution follows the successful clinical trials to determine its safety, efficacy and user satisfaction completed at MossRehab. With its international reputation for clinical rehabilitation and research programs, MossRehab was the exclusive clinical trial site in the United States for ReWalk; the trials will conclude in August 2011. The clinical information and experience gained from the trials cleared the way for this next exciting phase to begin, allowing many patients to benefit from this technological advancement.

    ReWalk is a lightweight, ergonomic brace-support suit that is worn around the legs and back and fits closely to the body on top of everyday clothing. The device has motorized hip and knee joints, rechargeable batteries, sensors and a computer-based patient-operated control system. Concurrent use of fore-arm crutches stabilizes the user during standing and walking and through simple, subtle body movements, the user can initiate and control movements for walking.


  3. #63
    The Transfection with GFP Gene and the Differentiation of Bone Marrow Stroma Cells into Neuron-like in Vitro

    Views: 1 | Article Submitted On: 07-26-2011

    Objective To study the isolation, purification, amplification and biological character of mesenchymal stem cells ( BMSC) form rat bone marrow. To study the possibility that transforming growth factor - β、 nerve growth factor and the traumatized spinal cord extracts (SCE) induces adult rat bone marrow stromal cells ( BMSC) into neurons for further investigation of an alternative for neuron regeneration and the treatment of spine cord injury. To explore the action of GFP labeled bone marrow stromal cells differentiate into neuron - like cells, which induced by transforming growth factor - βand nerve growth factor.Method(1) BMSC were isolated from the thighbone, shankbone of SD rats of 6 - 8 weeks, and were cultured in IMDM containing 100ml/L fetal bovine serum. They were purified by passage control and adhering to the culture plastic. We observed the growth status of BMSC, drew the growth curve, and analyzed the phenotype by immunocytochemistry. The bone marrow stromal cells from adult rats were isolated and cultured for 5 passages. The BMSC were incubated with IMDM containing 10% FRS and TGF - β( 1μg/L ) for 2 hours. Then the media were replaced by IMDM media consisting of NGF(50ng/mL). The morphological changes of the cells were observed under phase contrast microscope, the cells were stained immunocytochemically with NF,NSE and GFAP antibodies respectively.(2)The bone marrow stromal cells from adult rats were isolated and cul-tured for 5 passages.continue.....


  4. #64
    The Study of the Mechanism of Spinal Cord Injury and the Effect of Adenovirus-mediated GDNF Transfer in Vivo on Recovery of Motor Function Following Moderate Spinal Cord Injury

    The treatment of spinal cord injury is a problem that puzzled the orthopaedic scientists. The extent of initial damage to the spinal cord produced by a spinal cord injury depends on factors such as the mechanism of injury, force of the impact, cord displacement, acceleration, and kinetic energy of compression. The primary injury is followed by secondary injury mechanisms that are associated with physiological, biochemical, immunological, and cellular changes in the injured cord. Spinal cord compression and displacement from bone fragments, ligaments, or hematoma within the spinal canal may contribute to the initial damage by stimulating this secondary injury cascade. Mitigation of this secondary injury process by spinal cord decompression may be an important factor in the preservation of neurological function. Retrospective studies have demonstrated that surgical decompression increases neurological recovery. But there is no consensus regarding the most effective time-frame for intervention. Following the developing studies of spinal cord injury, scientists find out that the functional recovery depends on the preservation of neurons and the regeneration of axon. Neurotrophic factors, such as glial cell line-derived neurotrophic factor, can't cross the blood-brain barrier. Gene therapy is a new method following spinal cord injury. GDNF, a member of the transformation growth factor-βsuperfamily, is known to be the most active neurotrophic factor for motoneurons. The adenoviral vector is easy to be produced and is proven to mediate successful expression of target gene.continue........


  5. #65
    SEC Filing: Neuralstem Receives Russian Patent
    Posted July 25, 2011

    ROCKVILLE, Maryland - Neuralstem, Inc. (NYSE Amex: CUR) announced that it has received a patent covering the transplantation of human neural cells for the treatment of neurodegenerative conditions from the Russian Federation. The claims include methods of culturing the cells as well as treating amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), spinal cord injuries, traumatic brain injury, multiple sclerosis, cerebral palsy, epilepsy, Huntington's disease and other conditions through cell transplantation. Neuralstem is currently sponsoring the world's first FDA-approved trial to treat ALS with its spinal cord stem cells and has applied to the FDA to initiate a stem cell trial in chronic spinal cord injury.


  6. #66
    New Treatment Restores Movement to Persons with Stroke and Spinal Cord Injury-Dr. Paul Cordo-08/02/2011 - 8:30am

    Event Information
    Event Topic:
    New Treatment Restores Movement to Persons with Stroke and Spinal Cord Injury
    Event Date:
    08/02/2011 - 8:30am
    Event Location:
    Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA Speaker Information
    Event Speaker:
    Dr. Paul Cordo
    Event Speaker Title:
    Event Speaker Company:
    AMES Technology
    Event Speaker Bio:

    Imagine you hit a chuckhole with your car and blow out a tire, throw off the alignment, and damage the power steering mechanism. The car doesn’t drive very well anymore. This is a little like having an injury to your central nervous system (CNS): you can’t move very well anymore, and there are multiple causes of your movement deficit. The conventional physical and occupational therapeutic approach would be to hang a heavy weight from the side of the car opposite to the damage, put a piano dolly under the axle on the damaged side, and drive the car around a lot so it learns how to function with your jerry-rigging and, somehow over time, it fixes itself! Any guesses how well this works?.


  7. #67
    Underwater-Treadmill Therapy Nets Remarkable Improvement in Mobility After Spinal-Cord Trauma
    Released: 7/26/2011 9:00 AM EDT
    Source: Middle Tennessee State University

    Newswise — The result of research often is shown in hard and fast metrics. For Janette Rodgers, the only metric she cares about is that her wheelchair, once her prison day in and day out, now sits empty 90 percent of the time— in large part because of the hours she spent in 270 gallons of water.

    After suffering a broken neck and spinal-cord damage in a car accident in 2007, Rodgers, 53, was nearly taken off life-support. Later, doctors told her she would never walk again. A year later, she was a participant in Dr. Sandra Stevens’ underwater-treadmill study at Middle Tennessee State University where she gradually managed to take a few steps with assistance.

    Today, Rodgers’ husband, Terry, watches as his wife walks 500 feet every day to the mailbox at their home in Rockvale, Tenn.


  8. #68
    NeuroMetrix Announces Acquisition of Technology and Intellectual Property Assets for Regeneration of Peripheral Nerves and Spinal Cord, and Treatment of Nervous System Injuries

    WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), a science-based medical device company advancing patient care through the development and marketing of innovative products that aid physicians in the assessment and treatment of diseases and injuries of peripheral nerves, and that provide regional anesthesia and pain control, announced today that it has acquired certain technological and intellectual property assets from Cyberkinetics Neurotechnology Systems, Inc. and Andara Life Science, Inc., a wholly-owned subsidiary of Cyberkinetics, for $350,000 in cash.

    The acquired assets include all of Cyberkinetics’ rights and regulatory filings for the Andara™ Oscillating Field Stimulator (OFS™) technology for treatment of acute spinal cord injury, an investigational device designed to stimulate spinal cord repair and restore sensation; the rights to develop and commercialize a therapeutic product for peripheral nerve injury based on the Andara OFS neurostimulation technology; development and commercialization rights to certain derivatives of the pharmacological agent 4-aminopyridine that may be useful in the treatment of central and peripheral nervous system injury and disease; and certain other intellectual property and technology.

    Shai N. Gozani, M.D., Ph.D, NeuroMetrix's President and CEO said, “NeuroMetrix's core mission is to develop and market products in three clinical areas related to the nervous system. The first is diagnosis and monitoring of peripheral nerve and spinal cord dysfunction. The second is the delivery of anesthetic and therapeutic agents to peripheral nerves and the spine. And the third, which we have significantly strengthened through this acquisition of the Andara OFS technology, is neurostimulation to promote repair and regeneration of peripheral nerves and the spinal cord. These three areas have a common scientific theme which is the measurement, modulation, and repair of neural conduction.”

    Dr. Gozani continued, “NeuroMetrix has successfully developed and commercialized two widely used proprietary neurodiagnostic products, including the ADVANCE™ NCS/EMG System. Our diagnostic devices are used by over 15,000 physicians. NeuroMetrix has additional products in development, including ASCEND™ which is a device for localization of nerves during regional anesthesia, treatment of neuropathies, and pain control. By adding the Andara OFS neurostimulation platform to our product pipeline, this acquisition has the potential to diversify our business and help us become a leading neurotechnology company.”


  9. #69


    scary picture, I want the natural cure.

    'Brain Cap' Technology Turns Thought Into Motion; Mind-Machine Interface Could Lead to New Life-Changing Technologies for Millions of People

    ScienceDaily (July 27, 2011) — "Brain cap" technology being developed at the University of Maryland allows users to turn their thoughts into motion. Associate Professor of Kinesiology José 'Pepe' L. Contreras-Vidal and his team have created a non-invasive, sensor-lined cap with neural interface software that soon could be used to control computers, robotic prosthetic limbs, motorized wheelchairs and even digital avatars.

    "We are on track to develop, test and make available to the public- within the next few years -- a safe, reliable, noninvasive brain computer interface that can bring life-changing technology to millions of people whose ability to move has been diminished due to paralysis, stroke or other injury or illness," said Contreras-Vidal of the university's School of Public Health.


  10. #70
    CIRM: California stem cell funding institute may fund clinical trial


    The clinical trial grant under consideration Wednesday would provide almost $25 million to a California company that is developing a spinal cord injury treatment derived from human embryonic stem cells. According to a summary of the company's application posted on CIRM's website, patients with paralysis from spinal cord injuries will receive increasing doses of stem-cell-derived oligodendrocyte progenitor cells, which can help stimulate growth of nerve cells after injury and also produce myelin, insulation that helps electrical signals travel through nerve cells. Researchers have found that paralyzed rats treated with such progenitor cells can regain their ability to walk and run.


Similar Threads

  1. Replies: 0
    Last Post: 08-14-2005, 09:16 AM
  2. New articles posted to Research Forums.
    By Wise Young in forum Cure
    Replies: 1
    Last Post: 04-15-2004, 11:41 AM
  3. Replies: 0
    Last Post: 01-14-2004, 12:00 PM
  4. Replies: 8
    Last Post: 05-15-2003, 02:05 AM
  5. Replies: 1
    Last Post: 05-12-2002, 04:07 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts